Table 2 Clinical details on the two seronegative patients prior to booster.
Patient 1 | Patient 2 | |
|---|---|---|
Age at vaccination | 49 | 48 |
Sex | M | M |
Time since last vaccine dose (months) | 1.5 | 19 |
Time since transplant at booster (months) | 11 | 38 |
Number of previous vaccine doses post allo-HSCT | 2 | 4 |
Previous COVID-19 infection | no | yes |
Number of vaccine doses prior to allo-HSCT | 4 | 0 |
Diagnosis | AML1 | MCL2 |
Conditioning intensity | MAC3 | MAC |
Stem cell donor | MMRD4 (haplo) | URD (10/10)5 |
Stem cell source | BM6 | PB7 |
cGvHD8 | Severe extensive | Severe extensive |
Immunosuppression | Ruxolitinib 10mgx2, Prednisone 5mgx1 | Ruxolitinib 10mgx2 Prednisone 5mgx1 Photopheresis 2/2weeks |
sIgG prior to booster | 0 | 0 |
sIgG post booster | 26 | 10 286 |
nIgG prior to booster | 0 | 0 |
nIgG post booster | 0 | 0 |
T-cell reactivity prior to booster (IL-2) | 8.3 | 39.3 |
T-cell reactivity post booster (IL-2) | 5.3 | 3004.8 |
T-cell reactivity prior to booster (IFN-y) | 0 | 1.5 |
T-cell reactivity post booster (IFN-y) | 0 | 31.4 |
Adverse events following vaccination | none | none |
